DALLAS, Nov. 13, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hard To Treat Diseases Inc. (Pink Sheets:HTDS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Hard To Treat Diseases Inc. (Pink Sheets:HTDS) should be of particular interest to other biotechnology companies: Aastrom Biosciences Inc. (Nasdaq:ASTM), Cypress Bioscience Inc. (Nasdaq:CYPB) and Inovio Biomedical Corp. (NYSE:INO).
The full report is available at: http://www.investorsoup.com/lp/HTDS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Hard To Treat Diseases (HTDS) operates two medical subsidiaries in Serbia, Europe and Mainland China. HTDS is a parent company with operations in an East European medical company (Serbia) Slavica Bio Chem Co (formerly ReNuYu Biochmem PLC and ReNuYu Biochem Inc) and in China Mellow Hope Inc.
Message Board Search for HTDS: http://www.boardcentral.com/boards/HTDS
In the report, the analyst notes:
"HTDS' merger negotiations with the EU based stem cell research company are well underway. The HTDS representatives have scheduled meetings and the start of Due Diligence for November 23-25, 2009. HTDS management is exploring various options of this lucrative deal. The scenario which HTDS management is currently favoring includes a hybrid of technology -- revenue sharing model. This it would achieve through its Slavica Bio Chem subsidiary which would earn HTDS licensing revenues. This hybrid mechanism merger would leave HTDS' share structure undisturbed while at the same time HTDS' would earn fees for technology and services exchanged.
"In other Company news, since September 24, 2009, when Chinese State Food and Drug Administration granted the H1N1 vaccine license to Mellow Hope's exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co. Ltd., Mellow Hope received inquiries from many potential buyers around the world. At the present, the most promising deals on the horizon include deals with Southeast Asia and Chile. Mellow Hope is the largest exporter of vaccines in China and the H1N1 vaccine license gives the company a great advantage over the competition. The company expects to make progress announcements on the H1N1 front shortly."
To read the entire report visit: http://www.investorsoup.com/lp/HTDS
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.